Zentralblatt fur Chirurgie · 2003
[Systemic treatment for hepatocellular carcinoma].
СтатьяОбзорНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Spangenberg H C, Zuber-Jerger I, Thimme R, Blum H E, Von Weizsäcker F
Аннотация
Hepatocellular carcinoma (HCC) is one of the most frequent malignancies worldwide. A variety of pharmacological strategies has been evaluated in the treatment of HCC: classical chemotherapy, tamoxifen, octreotide, thymostimulin, pravastatin, (131)I-lipiodol as well as transarterial chemoperfusion (TAC) and chemoembolisation (TACE). TACE monotherapy or TACE combined with pravastatin resulted in a survival benefit of selected HCC patients. New strategies such as immunotherapy, antiangiogenic agents or cyclooxygenase inhibitors are under clinical investigation and might play a role in future therapies for HCC. Efficient strategies for the primary prevention of HCC are available and promising concepts in the secondary prevention have been reported.
Предметные рубрики MeSH
Adjuvants, ImmunologicAngiogenesis InhibitorsAnimalsAntibiotics, AntineoplasticAnticholesteremic AgentsAntineoplastic Agents, HormonalCarcinoma, HepatocellularChemoembolization, TherapeuticCyclohexanesDisease Models, AnimalGenetic TherapyHumansImmunotherapyLiver NeoplasmsMeta-Analysis as TopicMiceMulticenter Studies as TopicO-(Chloroacetylcarbamoyl)fumagillolOctreotidePilot ProjectsPravastatinPrimary PreventionPrognosisRandomized Controlled Trials as TopicRisk FactorsSesquiterpenesTamoxifenThymus ExtractsTime Factors